购物车
- 全部删除
- 您的购物车当前为空
Anti-VEGFR3/FLT4 Antibody (7C228) 是一种 Rabbit 抗体,靶向 VEGFR3/FLT4。Anti-VEGFR3/FLT4 Antibody (7C228) 可用于 ELISA。
Anti-VEGFR3/FLT4 Antibody (7C228) 是一种 Rabbit 抗体,靶向 VEGFR3/FLT4。Anti-VEGFR3/FLT4 Antibody (7C228) 可用于 ELISA。
产品描述 | Anti-VEGFR3/FLT4 Antibody (7C228) is a Rabbit antibody targeting VEGFR3/FLT4. Anti-VEGFR3/FLT4 Antibody (7C228) can be used in ELISA. |
Ig Type | Monoclonal Rabbit IgG |
克隆号 | 7C228 |
交叉反应 | Mouse |
应用 | ELISA |
推荐剂量 | ELISA: 1:5000-1:10000 |
抗体种类 | Monoclonal |
宿主来源 | Rabbit |
构建方式 | This antibody was obtained from a rabbit immunized with purified, recombinant Mouse VEGFR3 / FLT-4 (rM VEGFR3 / FLT-4; TMPY-01936; P35917-1; Met1-Glu775). |
纯化方式 | Protein A |
性状 | Liquid |
缓冲液 | 0.2 μm filtered solution in PBS |
研究背景 | Vascular endothelial growth factor receptor 3 (VEGFR3), also known as FLT-4, together with the other two members VEGFR1 (FLT-1) and VEGFR2 (KDR/Flk-1) are receptors for vascular endothelial growth factors (VEGF) and belong to the class III subfamily of receptor tyrosine kinases (RTKs). The VEGFR3 protein is expressed mainly on lymphatic vessels but it is also up-regulated in tumor angiogenesis. Mutations in VEGFR3 have been identified in patients with primary lymphoedema. The VEGF-C/VEGF-D/VEGFR3 signaling pathway may provide a target for antilymphangiogenic therapy in prostate cancer, breast cancer, gastric cancer, lung cancer, non-small cell lung cancer (NSCLC), and so on.Cancer ImmunotherapyImmune CheckpointImmunotherapyTargeted Therapy |
偶联 | Unconjugated |
免疫原 | Recombinant Mouse VEGFR3 / FLT-4 protein (TMPY-01936) |
抗原种属 | Mouse |
研究领域 | Cancer Drug Targets, Receptor Tyrosine Kinases (RTKs) |
储存方式 | Store at 2°C-8°C for 1 month. Store at -20°C or -80°C for 12 months. Avoid repeated freeze-thaw cycles. Preservative-Free. |
运输方式 | Shipping with blue ice. |
评论内容